Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
benaraglutide + sitagliptin
- Development stage
- Preclinical
- Lead developer
- Shanghai Benemae Pharmaceutical
- Modality
- Peptides, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
This is a fixed-dose combination of benaraglutide, a short-acting glucagon-like peptide 1 receptor agonist (GLP-1RA), and sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Benaraglutide mimics endogenous GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite. Sitagliptin inhibits DPP-4 enzyme activity, thereby increasing endogenous incretin levels (including GLP-1), which further enhances insulin secretion and reduces glucagon levels in response to meals. The combination targets multiple pathophysiological mechanisms in type 2 diabetes mellitus (T2DM) for improved glycemic control with low risk of hypoglycemia and potential weight loss benefits[3][7][8]. Both agents are recommended by Chinese and international guidelines for T2DM management.
- Other names
- 贝那鲁肽联合西格列汀
02
Targets
Beyond the preview
Go deeper on benaraglutide + sitagliptin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on benaraglutide + sitagliptin.